Prophylactic use reduced annualized bleeding in hemophilia A and B pts with inhibitors. Concizumab is an anti–tissue factor pathway inhibitor monoclonal antibody.
Another interesting article on benign hematology, this one is about gene therapy in Hemophilia B.
FCS Hematology Oncology Review creates a platform for our physician network to observe the most recent articles and studies available in the oncology and hematology world. By sharing these articles we are building our wealth of knowledge of new observations and treatments as they come available.
